Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 5Phase 2/3 2Phase 1/2 2Phase NA 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 3Neoplasms 2Hematologic Neoplasms 2HER2-positive Breast Cancer 2Urinary Bladder Neoplasms 1Stomach Neoplasms 1Skin Neoplasms 1Salivary Gland Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms by Histologic Type 1Lymphoproliferative Disorders 1Lung Neoplasms 1Gallbladder Neoplasms 1Colorectal Neoplasms 1

Interventions

Trastuzumab 3pertuzumab 2Docetaxel 2tucatinib 1Protons 1Paclitaxel 1Carboplatin 1Capecitabine 1ARX788 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × HER2-positive Breast Cancer × pertuzumab × Clear all
NCT06891833 2025-10-02

A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2/3 Recruiting
120 enrolled
Breast

HER2-positive Breast Cancer

NCT05426486 2024-10-30

A Study of ARX788 Combined With Pyrotinib Maleate Versus TCBHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

Shengjing Hospital

Phase 2/3 Active not recruiting
136 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡